Relates to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy

2025 Regular Session Introduced by Harry Bronson and 11 co-sponsors

Bill A 6927 mandates clearer prescription labels for hormone-related medications, enhancing patient safety and education to improve treatment adherence and health outcomes.

REFERRED TO HIGHER EDUCATION

Summary of Bill A 6927

Bill Number: A 6927
Title: Relates to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy
Status: Referred to Higher Education
Introduced: March 18, 2025
Classification: Bill
Related Bills: S 6422 (companion)

Purpose and Intent

Bill A 6927 aims to enhance the clarity and safety of prescription labels for specific classes of medications that are commonly used in hormone therapy and related treatments. The bill focuses on ensuring that patients receive comprehensive information about their medications, particularly those that may have significant implications for hormonal health and development.

Key Provisions

The bill proposes the following key changes regarding prescription labels:

Enhanced Labeling Requirements:

Prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, and hormone replacement therapy drugs must include detailed information about the medication's purpose, potential side effects, and usage instructions.

Patient Education:

The bill emphasizes the importance of patient education, requiring that labels provide clear guidance on how to use the medication safely and effectively.

Standardization of Information:

The legislation seeks to standardize the information presented on labels across different medications within the specified classes to ensure consistency and improve patient understanding.

Who Would Be Affected

Patients: Individuals prescribed the specified medications will benefit from clearer and more informative labels, which could lead to better adherence to treatment and improved health outcomes.

Healthcare Providers: Physicians, pharmacists, and other healthcare professionals will need to adapt to the new labeling requirements, ensuring that they provide patients with the necessary information about their prescriptions.

Pharmaceutical Companies: Manufacturers of the specified medications will be required to comply with the new labeling standards, which may involve revising existing labels and packaging.

Procedural Aspects

Legislative Process: The bill was introduced on March 18, 2025, and has been referred to the Higher Education committee for further consideration.

Timeline: As of now, there are no specified dates for further hearings or votes, but the bill's progress will depend on the committee's schedule and legislative priorities.

Conclusion

Bill A 6927 represents a significant step towards improving patient safety and education regarding hormone-related therapies. By mandating clearer prescription labels, the bill aims to empower patients with the knowledge they need to manage their health effectively. The outcome of this bill will depend on its reception in the Higher Education committee and subsequent legislative actions.